Abaxis Inc Revenue Growth Rates (ABAX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Abaxis Inc  (ABAX)
 

ABAX's Revenue Growth by Quarter and Year

Abaxis Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ABAX Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
4th Quarter March 67.92
3rd Quarter December 59.67
2nd Quarter September 58.85
1st Quarter June 58.26
FY 244.70

ABAXs Annual Revenue
Abaxis Inc's Revenue in the fiscal year 2018 $ 244.70 millions
Abaxis Inc's Revenue in the fiscal year 2017 $ 227.22 millions
Abaxis Inc's Revenue in the fiscal year 2016 $ 218.90 millions
Abaxis Inc's Revenue in the fiscal year 2015 $ 202.59 millions
Abaxis Inc's Revenue in the fiscal year 2014 $ 171.87 millions




ABAX Revenue fourth quarter 2018 Y/Y Growth Comment
Abaxis Inc achieved in the fourth quarter 2018, above Company average Revenue increase of 16.7% year on year, to $ 67.92 millions.

Looking into fourth quarter 2018 results within Laboratory Analytical Instruments industry 8 other companies have achieved higher Revenue growth. While Abaxis Inc' s Revenue growth of 16.7% ranks overall at the positon no. 1460 in the fourth quarter 2018.


ABAX Revenue ( Y/Y Growth %) 2018
 2017 2016 2015
4th Quarter March 16.7 % 2.18 % 9.5 % 32.64 %
3rd Quarter December 13.08 % -0.21 % -11.13 % 45.8 %
2nd Quarter September 0.51 % 4.59 % 3.78 % 17.64 %
1st Quarter June 0.97 % 8.68 % 11.82 % 9.98 %
FY   7.69 % 3.8 % 2.8 % -

Financial Statements
Abaxis Inc's fourth quarter 2018 Revenue $ 67.92 millions ABAX's Income Statement
Abaxis Inc's fourth quarter 2017 Revenue $ 58.20 millions Quarterly ABAX's Income Statement


ABAX Revenue (Quarter on Quarter Growth %)

 2018
 2017 2016 2015
4th Quarter March 13.82 % 10.29 % 7.72 % -12.57 %
3rd Quarter December 1.39 % -9.87 % -5.54 % 10.31 %
2nd Quarter September 1.01 % 1.47 % 5.44 % 13.61 %
1st Quarter June 0.1 % 1.3 % 2.06 % 21.06 %
FY (Year on Year)   7.69 % 3.8 % 2.8 % -


Back to ABAX Growth rate Comparisons >> Back to ABAX Growth rate Comparisons >>


Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #238
Overall #1460

Revenue Y/Y Growth Statistics
High Average Low
45.8 % 9.75 % -21.49 %
(Dec 31 2014)   (Dec 31 2013)
Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #238
Overall #1460
Revenue Y/Y Growth Statistics
High Average Low
45.8 % 9.75 % -21.49 %
(Dec 31 2014)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Abaxis Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
27.4 % -1.68 % -100 %
(Jun 30 2015)  


ABAX's IV. Quarter Q/Q Revenue Comment
Abaxis Inc achieved in the IV. Quarter 2018 above company average sequential Revenue rise of 13.82%, to $ 67.92 millions, from $59.67 millions in the third quarter.
ABAX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Abaxis Inc's Revenue growth quarter on quarter, overall rank is 721.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #5
Healthcare Sector #107
Overall #721
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #5
Healthcare Sector #107
Overall #721
Revenue Q/Q Growth Statistics
High Average Low
27.4 % -1.68 % -100 %
(Jun 30 2015)  


ABAX's IV. Quarter Q/Q Revenue Comment
Abaxis Inc achieved in the IV. Quarter 2018 above company average sequential Revenue rise of 13.82%, to $ 67.92 millions, from $59.67 millions in the third quarter.
ABAX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Abaxis Inc's Revenue growth quarter on quarter, overall rank is 721.


Abaxis Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2018)		 12 Months Ending
(Dec 31 2017)		 12 Months Ending
(Sep 30 2017)		 12 Months Ending
(Jun 30 2017)		 12 Months Ending
(Mar 31 2017)
Cumulative Revenue 12 Months Ending $ 244.70 $ 234.98 $ 228.08 $ 227.78 $ 227.22
Y / Y Revenue Growth (TTM) 7.69 % 3.98 % 0.88 % 1.91 % 3.8 %
Year on Year Revenue Growth Overall Ranking # 1561 # 2483 # 2088 # 1874 # 1837
Seqeuential Revenue Change (TTM) 4.14 % 3.02 % 0.13 % 0.25 % 0.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 2764 # 1706 # 2582 # 2501 # 745


Cumulative Revenue growth Comment
Abaxis Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 7.69% year on year, to $ 245 millions if the fiscal year would have ended in Mar 31 2018.
Abaxis Inc's trailing twelve months Revenue growth was higher than company's average 6.07% and higher than 3.98% growth in Dec 31 2017.
But from twelve months ended Dec 31 2017 rise was beneth at 4.14 % from $234.98 millions achieved in the period from Dec 31 2017 to Mar 31 2017.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.07%.
The momentum is even more impressive from twelve months ended Dec 31 2017 exhibited at 4.14 % increase from $234.98 millions in the period from Dec 31 2017 to Mar 31 2017.

In the Healthcare sector 221 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1561, from total ranking in previous quarter at 2483.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 222
Overall # 1561

Revenue TTM Y/Y Growth Statistics
High Average Low
18.18 %
 6.07 %
-7.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 330
S&P 500 # 2764
Cumulative Revenue growth Comment
Abaxis Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 7.69% year on year, to $ 245 millions if the fiscal year would have ended in Mar 31 2018.
Abaxis Inc's trailing twelve months Revenue growth was higher than company's average 6.07% and higher than 3.98% growth in Dec 31 2017.
But from twelve months ended Dec 31 2017 rise was beneth at 4.14 % from $234.98 millions achieved in the period from Dec 31 2017 to Mar 31 2017.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.07%.
The momentum is even more impressive from twelve months ended Dec 31 2017 exhibited at 4.14 % increase from $234.98 millions in the period from Dec 31 2017 to Mar 31 2017.

In the Healthcare sector 221 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1561, from total ranking in previous quarter at 2483.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 222
Overall # 1561

Revenue TTM Y/Y Growth Statistics
High Average Low
18.18 %
6.07 %
-7.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 330
S&P 500 # 2764




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ABAX's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Mar 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2018
Orasure Technologies Inc29.01%$ 29.008 millions
Seagen Inc 28.83%$ 28.827 millions
Sorrento Therapeutics Inc 28.15%$ 28.149 millions
Nevro Corp 28.05%$ 28.048 millions
Nanostring Technologies Inc 27.80%$ 27.803 millions
Tetraphase Pharmaceuticals Inc27.34%$ 27.340 millions
Carlisle Companies Incorporated27.22%$ 27.222 millions
Ani Pharmaceuticals Inc26.91%$ 26.906 millions
Cytokinetics Incorporated26.85%$ 26.848 millions
Amarin Corp Plcuk26.80%$ 26.798 millions
Oncomed Pharmaceuticals Inc26.33%$ 26.332 millions
Intuitive Surgical Inc 25.70%$ 25.705 millions
Skinvisible Inc 24.94%$ 24.936 millions
Ionis Pharmaceuticals Inc 24.71%$ 24.714 millions
Syndax Pharmaceuticals Inc 24.26%$ 24.262 millions
Healthcare Services Group Inc 24.06%$ 24.060 millions
Orthopediatrics Corp23.89%$ 23.889 millions
Calithera Biosciences Inc 23.78%$ 23.783 millions
Plus Therapeutics Inc 23.69%$ 23.689 millions
Jrsis Health Care Corp23.40%$ 23.395 millions
Biomarin Pharmaceutical Inc22.95%$ 22.948 millions
Perspective Therapeutics Inc 22.70%$ 22.699 millions
Msa Safety Inc22.62%$ 22.625 millions
Sanara Medtech Inc 22.21%$ 22.211 millions
Chembio Diagnostics Inc 22.01%$ 22.007 millions
Veracyte Inc 21.96%$ 21.963 millions
Amneal Pharmaceuticals Inc 21.94%$ 21.937 millions
Vystar Corporation21.88%$ 21.879 millions
Cytomx Therapeutics Inc 21.72%$ 21.720 millions
Viveve Medical Inc 21.64%$ 21.638 millions


About Abaxis Inc Revenue Growth Rates (ABAX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.